Fuzeon Discontinuations From Injection Reactions Remain Low At 48 Weeks
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche/Trimeris’ 48-week follow-up data for Fuzeon show a continued low rate of discontinuation due to injection site reactions.